<DOC>
	<DOCNO>NCT01563081</DOCNO>
	<brief_summary>To evaluate safety treatment levocetirizine oral solution pediatric patient age form 6 month 2 year old allergic rhinitis pruritus associate skin disease .</brief_summary>
	<brief_title>Safety Study Levocetirizine Oral Solution Japanese Pediatrics</brief_title>
	<detailed_description>This multi-center , open-labelled study confirm safety main objective , consist minimum 1-week screening period 2-week treatment period . The subject meet inclusion criterion place one follow two regimen accord age start treatment period : daily administration levocetirizine dose 1.25 mg ( morning ) infant age 6 month 1 year old ( young age group ) , twice daily administration levocetirizine dose 1.25 mg ( morning , even sleep ) infant age 1 year 2 year old ( old age group ) .</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Outpatients Either boys girl acceptable . Pediatric patient range 6 month 2 year age time initiation treatment clinical trial Pediatric patient least one symptom associate allergic rhinitis include rhinorrhea , nasal congestion sneezing , require least 2week treatment antihistamine drug , suffer pruritus associate following disease require least 2week treatment antihistamine drug ( Chronic urticaria , Eczema/dermatitis group : atopic dermatitis etc . [ A diagnosis atopic dermatitis make accordance `` Definition/Diagnostic Criteria Atopic Dermatitis , Prurigo group : acute prurigo ( strophulus , urticarialike lichen , etc . ) , subacute prurigo , chronic prurigo ( nodular prurigo etc . ) , Pruritus cutaneous : systemic pruritus cutaneous , local pruritus cutaneous ) Pediatric patient QTc interval 450 msec . QTc interval shall 480 msec pediatric patient bundle branch block screening ( A judgment shall make accord QTc interval base ECG result correspond one heart beat QTc interval base mean ECG result correspond 3 heart beat . ) AST &lt; 2×upper limit normal , ALT &lt; 2×upper limit normal , alkaline phosphatase≤1.5×upper limit normal , bilirubin≤1.5×upper limit normal screening ( The serum bilirubin shall fraction direct bilirubin shall 35 % . In case , free bilirubin level exceed 1.5 time upper limit normal acceptable . ) Pediatric patient whose parent ( person parental authority guardian ) shall submit write informed consent Pediatric patient whose parent ( person parental authority guardian ) shall fill medication diary Pediatric patient whose body weight infantile growth curve show infant body growth investigation report 2011 [ MHLW , 2011 ] Pediatric patient breastfed mother take antihistamine drug study period Pediatric patient receive systemic adrenocorticosteroids within 28 day Visit 2 Pediatric patient currently treat plan immunotherapy initiate study period Pediatric patient abnormal laboratory result unrelated allergic disorder [ These patient enrol investigator ( subinvestigator ) judge enrolment pose clinical problem . ] Pediatric patient require application adrenocorticosteroids external use classify `` strong , '' `` strong '' `` strong '' Pediatric patient suffer asthma complication require treatment adrenocorticosteroids ( include adrenocorticosteroid combination ) Pediatric patient history convulsion , febrile convulsion sleep apnea Pediatric patient whose brother sisters history sleep apnea sudden infant death syndrome Pediatric patient history allergy hypersensitivity ingredient levocetirizine hydrochloride preparation piperazine derivative hydroxyzine , cetirizine , cyclizine Pediatric patient history drug hypersensitivity Pediatric patient consider inappropriate subject clinical trial liver disease , renal disease , heart disease complication pose clinical problem Pediatric patient whose parent minor Infants belong child 's institution Pediatric patient participate clinical trial 6 month enrolment intend participate clinical trial clinical trial period . Person meet follow criterion his/her family ( An employee GlaxoSmithKline K.K. , Investigator subinvestigator , An employee Site Management Organization ( SMO ) relate clinical study ) Other pediatric patient judged inappropriate participate clinical trial investigator ( subinvestigator )</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Allergic rhinitis</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Levocetirizine</keyword>
</DOC>